Amphastar Pharmaceuticals (AMPH) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Amphastar Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$712.81M

Latest Revenue (Q)

$170.53M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Amphastar Pharmaceuticals Revenue by Period

Amphastar Pharmaceuticals Revenue by Year

Date	Revenue	Change
2024-12-31	$712.81M	10.62%
2023-12-31	$644.39M	29.14%
2022-12-31	$498.99M	13.98%
2021-12-31	$437.77M	25.13%
2020-12-31	$349.85M	8.53%
2019-12-31	$322.36M	9.40%
2018-12-31	$294.67M	22.69%
2017-12-31	$240.18M	-5.87%
2016-12-31	$255.16M	1.45%
2015-12-31	$251.52M	19.51%
2014-12-31	$210.46M	-8.37%
2013-12-31	$229.68M	12.41%
2012-12-31	$204.32M	72.63%
2011-12-31	$118.36M	-

Amphastar Pharmaceuticals generated $712.81M in revenue during NA 2024, up 10.62% compared to the previous quarter, and up 221.13% compared to the same period a year ago.

Amphastar Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2025-03-31	$170.53M	-8.58%
2024-12-31	$186.52M	-1.22%
2024-09-30	$188.82M	3.52%
2024-06-30	$182.39M	6.14%
2024-03-31	$171.84M	-3.52%
2023-12-31	$178.10M	-1.36%
2023-09-30	$180.56M	23.91%
2023-06-30	$145.71M	4.06%
2023-03-31	$140.02M	3.70%
2022-12-31	$135.02M	12.40%
2022-09-30	$120.13M	-2.70%
2022-06-30	$123.47M	2.57%
2022-03-31	$120.37M	-0.43%
2021-12-31	$120.89M	7.74%
2021-09-30	$112.20M	10.36%
2021-06-30	$101.66M	-1.32%
2021-03-31	$103.02M	7.40%
2020-12-31	$95.92M	14.97%
2020-09-30	$83.43M	-2.77%
2020-06-30	$85.81M	1.32%
2020-03-31	$84.69M	1.57%
2019-12-31	$83.38M	4.05%
2019-09-30	$80.14M	1.38%
2019-06-30	$79.05M	-0.93%
2019-03-31	$79.79M	-11.04%
2018-12-31	$89.69M	18.73%
2018-09-30	$75.54M	6.34%
2018-06-30	$71.04M	21.66%
2018-03-31	$58.39M	-3.33%
2017-12-31	$60.40M	4.29%
2017-09-30	$57.92M	-11.15%
2017-06-30	$65.19M	15.03%
2017-03-31	$56.67M	-10.82%
2016-12-31	$63.54M	-1.06%
2016-09-30	$64.22M	-5.60%
2016-06-30	$68.03M	14.60%
2016-03-31	$59.37M	-22.81%
2015-12-31	$76.91M	20.42%
2015-09-30	$63.87M	18.60%
2015-06-30	$53.85M	-5.33%
2015-03-31	$56.89M	1.81%
2014-12-31	$55.88M	-6.42%
2014-09-30	$59.71M	21.85%
2014-06-30	$49.00M	6.83%
2014-03-31	$45.87M	-16.41%
2013-12-31	$54.88M	-7.49%
2013-09-30	$59.32M	-5.13%
2013-06-30	$62.52M	18.05%
2013-03-31	$52.96M	-

Amphastar Pharmaceuticals generated $170.53M in revenue during Q1 2025, up -8.58% compared to the previous quarter, and up 95.75% compared to the same period a year ago.

Amphastar Pharmaceuticals Revenue Breakdown

Amphastar Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 20	Dec 19	Dec 18
Product	$712.81M	-	-	-
Other	$19.15M	-	-	-
Active Pharmaceutical Ingredient Segment	-	$18.48M	$20.36M	$23.61M

Amphastar Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (97.38%), and Other (2.62%).

Quarterly Revenue by Product

Product/Service	Jun 25	Mar 25	Dec 24	Sep 24	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18	Sep 18	Jun 18	Mar 18
Lidocaine	$15.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Epinephrine	$16.18M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total product revenues, net	$174.41M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Primatene MIST	$22.88M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Products	$53.07M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Glucagon	$20.60M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
BAQSIMI	$46.69M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development services	-	$100.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	-	-	$524.00M	$188.82M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	$2.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Active Pharmaceutical Ingredient Segment	-	-	-	-	$6.94M	$5.14M	$8.12M	$2.10M	$4.87M	$3.39M	$5.39M	$4.41M	$5.31M	$5.25M	$3.78M	$7.80M	$5.28M	-
Finished Pharmaceutical Products Segment	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$82.93M	-	-	-

Amphastar Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Total product revenues, net (50.00%), Other Products (15.21%), BAQSIMI (13.38%), Primatene MIST (6.56%), Glucagon (5.91%), Epinephrine (4.64%), and Lidocaine (4.30%).

Amphastar Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 20	Dec 19	Dec 18
CHINA	$4.34M	-	-	-
FRANCE	$19.95M	-	-	-
UNITED STATES	$707.68M	-	-	-
Active Pharmaceutical Ingredient Segment	-	$18.48M	-	-
C	-	$3.16M	$1.48M	-
U	-	$333.09M	$304.90M	$279.12M

Amphastar Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (96.68%), FRANCE (2.73%), and CHINA (0.59%).

Quarterly Revenue by Country

Country	Jun 25	Mar 25	Dec 24	Sep 24	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18	Jun 18	Mar 18
CHINA	$299.00K	$81.00K	$4.16M	$178.00K	-	-	-	-	-	-	-	-	-	-	-	-	-
FRANCE	$7.11M	$7.86M	$15.43M	$4.52M	-	-	-	-	-	-	-	-	-	-	-	-	-
UNITED STATES	$167.00M	$162.59M	$521.17M	$186.51M	-	-	-	-	-	-	-	-	-	-	-	-	-
U	-	-	-	-	$95.19M	$99.17M	$90.72M	$79.41M	$81.90M	$81.06M	$77.59M	$76.07M	$74.78M	$76.46M	$72.48M	$68.56M	$53.10M
Active Pharmaceutical Ingredient Segment	-	-	-	-	$6.94M	-	-	-	-	-	-	-	-	-	-	-	-
C	-	-	-	-	$1.13M	$1.12M	$679.00K	$1.96M	$295.00K	$228.00K	$438.00K	$59.00K	$984.00K	-	-	-	-

Amphastar Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 25: UNITED STATES (95.75%), FRANCE (4.08%), and CHINA (0.17%).

Amphastar Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RDY	Dr. Reddy's Laboratories	$279.16B	-
ALKS	Alkermes	$1.56B	$390.66M
AMPH	Amphastar Pharmaceuticals	$712.81M	$170.53M
PCRX	Pacira BioSciences	$700.97M	$181.10M
COLL	Collegium Pharmaceutical	$631.45M	$177.76M
ANIP	ANI Pharmaceuticals	$614.38M	$197.12M
ANGO	AngioDynamics	$292.50M	$72.00M

AMPH Revenue FAQ

What is Amphastar Pharmaceuticals’s yearly revenue?

Amphastar Pharmaceuticals's yearly revenue for 2024 was $712.81M, representing an increase of 10.62% compared to 2023. The company's yearly revenue for 2023 was $644.4M, representing an increase of 29.14% compared to 2022. AMPH's yearly revenue for 2022 was $498.99M, representing an increase of 13.98% compared to 2021.

What is Amphastar Pharmaceuticals’s quarterly revenue?

Amphastar Pharmaceuticals's quarterly revenue for Q1 2025 was $170.53M, a -8.58% decrease from the previous quarter (Q4 2024), and a -0.76% decrease year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $186.52M, a -1.22% decrease from the previous quarter (Q3 2024), and a 4.73% increase year-over-year (Q4 2023). AMPH's quarterly revenue for Q3 2024 was $188.82M, a 3.52% increase from the previous quarter (Q2 2024), and a 4.58% increase year-over-year (Q3 2023).

What is Amphastar Pharmaceuticals’s revenue growth rate?

Amphastar Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 42.85%, and for the last 5 years (2020-2024) was 103.75%.

What are Amphastar Pharmaceuticals’s revenue streams?

Amphastar Pharmaceuticals's revenue streams in c 24 are Product, and Other. Product generated $712.81M in revenue, accounting 97.38% of the company's total revenue Other generated $19.15M in revenue, accounting 2.62% of the company's total revenue

What is Amphastar Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Amphastar Pharmaceuticals was Product. This segment made a revenue of $712.81M, representing 97.38% of the company's total revenue.